MBX
Price
$48.50
Change
-$1.96 (-3.88%)
Updated
Oct 23 closing price
Capitalization
2.34B
12 days until earnings call
Intraday BUY SELL Signals
SRRK
Price
$41.49
Change
-$0.47 (-1.12%)
Updated
Oct 23 closing price
Capitalization
5.05B
17 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

MBX vs SRRK

MBX vs SRRK Comparison Chart in %
View a ticker or compare two or three
VS
MBX vs. SRRK commentary
Oct 25, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MBX is a Hold and SRRK is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for MBX with price predictions
Oct 23, 2026

MBX sees MACD Histogram just turned negative

MBX saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 23, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 15 instances where the indicator turned negative. In 14 of the 15 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MBX as a result. In 26 of 29 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

MBX moved below its 50-day moving average on September 18, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MBX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for MBX entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MBX's RSI Oscillator exited the oversold zone, 8 of 8 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 23 of 27 cases where MBX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.

Following a +2.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where MBX advanced for three days, in 120 of 130 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

MBX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.703) is normal, around the industry mean (3.043). P/E Ratio (-20.464) is within average values for comparable stocks, (-1.361). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. MBX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MBX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for SRRK with price predictions
Oct 23, 2026

SRRK's RSI Indicator ascends from oversold territory

The RSI Indicator for SRRK moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 28 similar instances when the indicator left oversold territory. In 24 of the 28 cases the stock moved higher. This puts the odds of a move higher at 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for SRRK just turned positive on October 21, 2026. Looking at past instances where SRRK's MACD turned positive, the stock continued to rise in 39 of 51 cases over the following month. The odds of a continued upward trend are 76%.

Following a +6.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where SRRK advanced for three days, in 231 of 287 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

SRRK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Momentum Indicator moved below the 0 level on October 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SRRK as a result. In 83 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The 10-day moving average for SRRK crossed bearishly below the 50-day moving average on September 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SRRK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

The Aroon Indicator for SRRK entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. SRRK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.910) is normal, around the industry mean (3.043). P/E Ratio (-12.535) is within average values for comparable stocks, (-1.361). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Profit vs. Risk Rating rating for this company is 79 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SRRK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
SRRK: Fundamental Ratings
SRRK
OUTLOOK RATING
1..100
74
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
PROFIT vs RISK RATING
1..100
79
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
60
P/E GROWTH RATING
1..100
22
SEASONALITY SCORE
1..100
90

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
MBXSRRK
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 4 days ago
90%
Bullish Trend 4 days ago
80%
Declines
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
COMPARISON
Comparison
Oct 25, 2026
Stock price -- (MBX: $48.50 vs. SRRK: $41.49)
Brand notoriety: MBX and SRRK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MBX: 140% vs. SRRK: 59%
Market capitalization -- MBX: $2.34B vs. SRRK: $5.05B
MBX [@Biotechnology] is valued at $2.34B. SRRK’s [@Biotechnology] market capitalization is $5.05B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $132.8B. The average market capitalization across the [@Biotechnology] industry is $2.11B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MBX’s FA Score shows that 1 FA rating(s) are green while SRRK’s FA Score has 1 green FA rating(s).

  • MBX’s FA Score: 1 green, 4 red.
  • SRRK’s FA Score: 1 green, 4 red.
According to our system of comparison, MBX is a better buy in the long-term than SRRK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MBX’s TA Score shows that 4 TA indicator(s) are bullish while SRRK’s TA Score has 4 bullish TA indicator(s).

  • MBX’s TA Score: 4 bullish, 5 bearish.
  • SRRK’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both MBX and SRRK are a bad buy in the short-term.

Price Growth

MBX (@Biotechnology) experienced а -2.24% price change this week, while SRRK (@Biotechnology) price change was +3.98% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.24%. For the same industry, the average monthly price growth was -16.30%, and the average quarterly price growth was -16.78%.

Reported Earning Dates

MBX is expected to report earnings on Nov 05, 2026.

SRRK is expected to report earnings on Nov 10, 2026.

Industries' Descriptions

@Biotechnology (+1.24% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
MBX
Daily Signal:
Gain/Loss:
SRRK
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
AAPD9.890.03
+0.30%
Direxion Daily AAPL Bear 1X ETF (AAPD)
ATC19.19N/A
N/A
GraniteShares Autocallable COIN ETF (ATC)
BBRE102.00-0.23
-0.22%
JPMorgan BetaBuilders MSCI US REIT ETF (BBRE)
KLIP21.23-0.14
-0.66%
KraneShares KWEB Covered Call Strategy ETF (KLIP)
JCE16.90-0.17
-1.00%
Nuveen Core Equity Alpha Fund

MBX and

Correlation & Price change

A.I.dvisor indicates that over the last year, MBX has been loosely correlated with NAMS. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if MBX jumps, then NAMS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MBX
1D Price
Change %
MBX100%
-3.88%
NAMS - MBX
40%
Loosely correlated
-8.67%
IMVT - MBX
39%
Loosely correlated
-2.37%
SYRE - MBX
38%
Loosely correlated
-2.17%
PVLA - MBX
38%
Loosely correlated
-1.02%
SVRA - MBX
38%
Loosely correlated
-7.05%
More

SRRK and

Correlation & Price change

A.I.dvisor indicates that over the last year, SRRK has been loosely correlated with RYTM. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if SRRK jumps, then RYTM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SRRK
1D Price
Change %
SRRK100%
-1.12%
RYTM - SRRK
51%
Loosely correlated
-1.79%
PTGX - SRRK
44%
Loosely correlated
-0.79%
ARVN - SRRK
43%
Loosely correlated
-5.44%
CGON - SRRK
42%
Loosely correlated
-1.33%
VERA - SRRK
42%
Loosely correlated
-3.65%
More